JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-06-27 pm EDT
182.12 USD   -0.09%
08:12aMeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Linked Retinitis Pigmentosa Patients
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nigeria Receives 4.4 Million Doses of Covid-19 Vaccines

05/25/2022 | 04:06am EDT

The federal government yesterday received 4,400,000 doses of Johnson & Johnson COVID-19 vaccines donated by the Government and people of Spain to Nigeria.

Speaking at the brief ceremony to mark the formal delivery of the vaccines by the Spanish government, the Executive Director of the National Primary HealthCare Development Agency (NPHCDA), Dr. Faisal Shuaib said 29,651,708 eligible persons had received the first dose of the COVID-19 vaccines. This, he said represented 23.4 per cent of the eligible population.

He said the federal government was intensifying efforts to ensure that 70 per cent of the country's eligible population are vaccinated.

"It is in furtherance of this initiative and the commitment of the Government of Spain that we are here today to officially receive, on behalf of the federal government of Nigeria, 4,400,000 doses of Johnson & Johnson COVID-19 vaccines donated by the Government and people of Spain to Nigeria," he said.

Shuaib told the Spanish Ambassador, Juan Ignatio Sell, that the donation came when it was most needed as the country was rapidly ramping up full vaccination coverage.

He said the single-dose regimen of the Johnson & Johnson vaccine would enable the agency move rapidly towards achieving herd immunity.

Shuaib further gave update on COVID-19 vaccination saying: "As at today, the 24th of May 2022, 29,651,708 eligible persons have received the first dose of the COVID-19 vaccines, and this represents 23.4 per cent our eligible population. 14,179,966 persons have received the 2nd dose and 17,702,018 are fully vaccinated and represents 15.8% of our eligible population. 1,178,604 persons have received the booster dose."

Shuaib said the figures so far posted by the country was a far cry from the target of 70 per cent of the eligible population.

"However, these donations will help towards achieving our target. If we keep up with vaccination, the likely scenario is that even though the virus continues to evolve, the severity of the disease will reduce over time, as the immunity increases due to vaccination.

"But if majority of our eligible population in Nigeria and globally continue to remain unvaccinated, what we may see is that a more virulent and highly transmissible variant could emerge, sooner or later which would be worse than any variant seen."

Shuaib added that: "New estimates from the World Health Organisation (WHO) showed that the full death toll associated directly or indirectly with the COVID-19 pandemic which is described as excess mortality, between 1 January 2020 and 31 December 2021 globally was approximately 15 million (range 13.3 million to 16.6 million).

"This means that we lost about 15million persons globally within two years as a result of the pandemic. This is heart wrenching," he said.

Copyright This Day. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

All news about JOHNSON & JOHNSON
08:12aMeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
MT
06/27Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
AQ
06/24Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
MT
06/24Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
MT
06/24JOHNSON & JOHNSON'S JANSSEN : CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu..
DJ
06/23JOHNSON & JOHNSON : Renews Commitment to Fight Neglected Tropical Diseases, Investing in B..
PU
06/22WALL STREET STOCK EXCHANGE : Powell's tall order to reassure investors
06/22Daiwa Securities Starts Johnson & Johnson at Outperform With $180 Price Target
MT
06/22ANALYST RECOMMENDATIONS : Johnson & Johnson, NatWest, Home Depot, Kraft Heinz, Vodafone...
06/21TRANSCRIPT : Johnson & Johnson - Special Call
CI
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 499 M - -
Net income 2022 22 521 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 21,2x
Yield 2022 2,45%
Capitalization 479 B 479 B -
EV / Sales 2022 4,87x
EV / Sales 2023 4,58x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 182,12 $
Average target price 188,12 $
Spread / Average Target 3,29%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON6.56%479 678
ELI LILLY AND COMPANY17.88%293 110
PFIZER, INC.-12.63%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202
NOVO NORDISK A/S6.98%253 053